Literature DB >> 445425

Results of eleven years' experience with heated perfusion for melanoma of the extremities.

J S Stehlin, B C Giovanella, P D de Ipolyi, R F Anderson.   

Abstract

Eleven years have elapsed since we first added heat to regional perfusion for treatment of melanoma of the extremities. This report describes briefly our laboratory findings and our technique of hyperthermic perfusion and brings up to date the survival figures for the 165 patients (185 perfusions) which were originally reported in 1975 (Stehlin et al., Surg. Gynecol. Obstet., 122: 3--14, 1966). A dramatic increase in the survival rate is documented for those patients with recurrent melanoma confined to the extremities.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 445425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  [Microvascular perfusion of malignant tumors--a therapeutic measure for enhancing the hyperthermia effect?].

Authors:  B Endrich; F Hammersen; K Messmer
Journal:  Langenbecks Arch Chir       Date:  1988

2.  Isolation-perfusion of the liver with 5-fluorouracil.

Authors:  W F Sindelar
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

Review 3.  Hyperthermia in cancer therapy.

Authors:  J Otte
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

4.  Hyperthermia in the treatment of cancer.

Authors:  N M Bleehen
Journal:  Br J Cancer Suppl       Date:  1982-03

5.  The treatment of state I melanoma of the extremities with regional hyperthermic isolation perfusion.

Authors:  K A Janoff; D Moseson; J Nohlgren; C Davenport; C Richards; W S Fletcher
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

6.  Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.

Authors:  M Vaglini; F Belli; M Santinami; F Arienti; G Parmiani; L Persiani; N Santoro; M Grazia Inglese; F D'Elia; N Cascinelli
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.